What is the appropriate 3‑month suppressive antifungal regimen for a woman with recurrent vulvovaginal candidiasis (≥ 4 episodes in the past year) after addressing predisposing factors?

3-Month Suppressive Antifungal Regimen for Recurrent Vulvovaginal Candidiasis

Critical First Step: Confirm Species Before Starting Maintenance

Obtain vaginal cultures with species identification before initiating any suppressive regimen, because 10–20% of recurrent cases are caused by Candida glabrata, which is intrinsically resistant to fluconazole and will result in months of wasted therapy. 1, 2

Standard 3-Month Regimen (For Confirmed C. albicans)

The evidence-based 3-month suppressive regimen is fluconazole 150 mg orally once weekly for 12 weeks (3 months), initiated immediately after completing induction therapy. 1, 3

Induction Phase (Must Precede Maintenance)

Before starting weekly suppression, achieve clinical and mycologic remission with one of these induction options: 1, 3

• Fluconazole 150 mg orally on days 1,4, and 7 (preferred oral option), OR
• Any topical azole applied daily for 10–14 days (e.g., clotrimazole 1% cream 5 g, miconazole 2% cream 5 g, or terconazole 0.4% cream 5 g intravaginally) 1, 3

Maintenance Phase

• Fluconazole 150 mg orally once weekly for 12 consecutive weeks 1, 2, 3
• This regimen achieves symptom control in >90% of patients during the treatment period 1, 4
• At 6 months (which includes your 3-month treatment period), 90.8% of women remain disease-free compared to 35.9% with placebo 4

Alternative Maintenance Regimens (When Fluconazole Is Contraindicated)

If fluconazole cannot be used, consider these weekly alternatives for 3 months: 2, 3

• Clotrimazole 500 mg vaginal suppository once weekly, OR
• Itraconazole 400 mg orally once monthly (note: less frequent dosing), OR
• Ketoconazole 100 mg orally daily (requires liver enzyme monitoring; hepatotoxicity risk 1 in 10,000–15,000) 2, 3

Management of C. glabrata (Non-Albicans Species)

If cultures identify C. glabrata, do NOT use fluconazole. Instead: 1, 2, 3

• First-line: Boric acid 600 mg intravaginal gelatin capsule daily for 14–21 days (achieves 70% eradication) 1, 2, 3
• Second-line alternatives: Nystatin 100,000 U intravaginal suppository daily for 14 days, OR topical 17% flucytosine cream ± 3% amphotericin B cream daily for 14 days 1, 2, 3
• No established maintenance regimen exists for C. glabrata; repeat induction courses may be necessary 2

Expected Outcomes and Patient Counseling

Set realistic expectations: even with optimal 3-month suppressive therapy, 30–40% of women will experience recurrence after stopping treatment. 2, 3 The longer 6-month regimen (not 3-month) shows better durability, with median time to recurrence of 10.2 months versus 4.0 months with placebo. 4

Special Population Modifications

Pregnancy

• Oral fluconazole is absolutely contraindicated due to associations with spontaneous abortion and congenital malformations 1, 3
• Use only 7-day topical azole therapy (clotrimazole, miconazole, butoconazole, or terconazole); no maintenance regimen is recommended 1, 3
• Boric acid is also contraindicated in pregnancy 3

HIV-Positive Women

• Use identical diagnostic and therapeutic protocols as HIV-negative women; response rates are comparable 1, 3

Diabetes Mellitus

• Uncontrolled diabetes significantly impairs treatment response 3
• Optimize glycemic control before and during suppressive therapy 3

Critical Pitfalls to Avoid

• Never start empiric fluconazole maintenance without culture confirmation of species—you may be treating resistant C. glabrata for months 1, 2
• Do not treat asymptomatic Candida colonization (present in 10–20% of women); treatment is indicated only for symptomatic episodes 1
• Do not rely on wet-mount microscopy alone (sensitivity only 57.5%); obtain cultures for recurrent cases 2, 3
• Do not routinely treat sexual partners—vulvovaginal candidiasis is not sexually transmitted; partner treatment is indicated only for symptomatic balanitis 2, 3

Drug Interactions and Safety Monitoring

Fluconazole interacts with multiple medications, including: 3

• Calcium-channel antagonists
• Warfarin (monitor INR closely)
• Oral hypoglycemics
• Phenytoin
• Protease inhibitors
• Rifampin

Review all concomitant medications before initiating fluconazole therapy. 3

Follow-Up Strategy

• Schedule follow-up visits during the 3-month maintenance period to assess efficacy and adverse effects 2, 3
• Obtain repeat vaginal culture 1 month after completing therapy to confirm mycological cure, especially for C. glabrata cases 3
• Instruct patients to return if symptoms persist or recur within 2 months of starting therapy 1

Why 6 Months Is Preferred Over 3 Months

While you asked specifically about a 3-month regimen, the evidence strongly supports 6 months of weekly fluconazole as the standard maintenance duration. 1, 2, 3, 4 The landmark trial by Sobel et al. demonstrated that at 6 months, 90.8% remained disease-free, but by 9 months (3 months post-treatment), this dropped to 73.2%, and by 12 months to only 42.9%. 4 A 3-month regimen will likely result in earlier recurrence and may require retreatment sooner.